Inhibitor Therapeutics, Inc.

Inhibitor Therapeutics, Inc. held its 2026 Annual Meeting of Stockholders where directors were elected, the auditor was ratified, and the 2025 Share Incentive Plan was approved. Stockholders also provided advisory approval for executive compensation and indicated a preference for annual advisory votes on the matter. The elected directors will serve until the 2027 Annual Meeting.

Inhibitor Therapeutics, Inc. reported a net loss of $0.7 million for Q1 2026, with negative cash flows from operations of $1.1 million. The company's cash and cash equivalents decreased significantly to $1.3 million. Management has issued a going concern warning due to insufficient liquidity to sustain operations for the next year. A critical $3.0 million financing deal is currently in litigation after the institutional investor failed to provide funds, further exacerbating liquidity concerns.